Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

[Image: see text] Despite advances in precision medicine approaches over the past decade, the majority of nonsmall cell lung cancers (NSCLCs) are refractory to treatment with targeted small molecule inhibitors. Previous work has identified mutations in the Discoidin Domain Receptor 2 (DDR2) kinase a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ACS Chem Biol
Autors principals: Terai, Hideki, Tan, Li, Beauchamp, Ellen M., Hatcher, John M., Liu, Qingsong, Meyerson, Matthew, Gray, Nathanael S., Hammerman, Peter S.
Format: Artigo
Idioma:Inglês
Publicat: American Chemical Society 2015
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4685943/
https://ncbi.nlm.nih.gov/pubmed/26390252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acschembio.5b00655
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars